Haarwachstum unter Dupilumab bei Alopecia areata universalis und atopischer Dermatitis

We report the case of a 46-year-old woman who has suffered from severe atopic dermatitis since early childhood and from alopecia areata totalis since she was 18 years old, which has now developed into alopecia areata universalis. After the introduction of therapy with the monoclonal antibody dupilumab, renewed hair growth of the scalp, face and lower legs was observed. Dupilumab blocks the α‑subunit of interleukin (IL)-4 receptor and prevents the signaling cascade of IL‑4 and IL-13. This leads to a reduction of Th2 immune response. The severe eczema and itching with difficulties falling and staying asleep decreased after just 14 days. The patient tolerates the drug without significant side effects and has a significantly improved quality of life. Patients with severe atopic dermatitis and alopecia areata could benefit twice from the use of dupilumab in the future.